{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:08:27Z","timestamp":1791331707270,"version":"4.3.1"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Respir Med"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1007\/bf03256641","type":"journal-article","created":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T04:05:17Z","timestamp":1345694717000},"page":"75-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Cefepime"],"prefix":"10.1007","volume":"2","author":[{"given":"Therese M.","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,20]]},"reference":[{"key":"BF03256641_CR1","unstructured":"Elan. Maxipime: prescribing information [web page]. Available from: URL: http:\/\/www.elan.com\/Products\/Anti-infective\/Maxipime\/PI\/fn-pi.html. (accessed 2003 Jan 17)"},{"key":"BF03256641_CR2","unstructured":"Bristol-Myers Squibb. Corporate product labeling profile annotated: international (non-US) prescribing information, 2001 Dec 19 (Data on file)"},{"issue":"3","key":"BF03256641_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2165\/00003495-199447030-00007","volume":"47","author":"LB Barradell","year":"1994","unstructured":"Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994 Mar; 47(3): 471\u2013505","journal-title":"Drugs"},{"issue":"3","key":"BF03256641_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1300\/J100v02n03_02","volume":"2","author":"M Woods","year":"1997","unstructured":"Woods M. Cefepime: a new generation cephalosporin. J Infect Dis Pharmacother 1997; 2(No. 3): 5\u201328","journal-title":"J Infect Dis Pharmacother"},{"issue":"4","key":"BF03256641_CR5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0025-7125(16)30035-9","volume":"79","author":"BA Cunha","year":"1995","unstructured":"Cunha BA, Gill MV. Cefepime. Med Clin North Am 1995 Jul; 79(4): 721\u201332","journal-title":"Med Clin North Am"},{"issue":"Suppl.A","key":"BF03256641_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/29.suppl_A.1","volume":"29","author":"REW Hancock","year":"1992","unstructured":"Hancock REW, Bellido F. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother 1992 Apr; 29Suppl. A: 1\u20136","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl.2","key":"BF03256641_CR7","first-page":"31","volume":"8","author":"REW Hancock","year":"1996","unstructured":"Hancock REW, Bellido F. Antibacterial in vitro activity of fourth generation cephalosporins. J Chemother 1996; 8Suppl. 2: 31\u20136","journal-title":"J Chemother"},{"issue":"2","key":"BF03256641_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/AAC.34.2.337","volume":"34","author":"H Nikaido","year":"1990","unstructured":"Nikaido H, Liu W, Rosenberg EY. Outer membrane permeability and \u03b2-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother 1990 Feb; 34(2): 337\u201342","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/AAC.35.1.68","volume":"35","author":"F Bellido","year":"1991","unstructured":"Bellido F, Pech\u00e8re J-C, Hancock REW. Novel method for measurement of outer membrane permeability to new \u03b2-lactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991 Jan; 35: 68\u201372","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"BF03256641_CR10","first-page":"503","volume":"29","author":"JG Gillum","year":"1994","unstructured":"Gillum JG, Polk RE. Focus on cefepime: a fourth generation, extended-spectrum cephalosporin. Hosp Formul 1994; 29(7): 503\u201314","journal-title":"Hosp Formul"},{"issue":"10","key":"BF03256641_CR11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1128\/AAC.37.10.2045","volume":"37","author":"NH Georgopapadakou","year":"1993","unstructured":"Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to \u03b2-lactams. Antimicrob Agents Chemother 1993 Oct; 37(10): 2045\u201353","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR12","first-page":"369","volume":"17","author":"CC Sanders","year":"1993","unstructured":"Sanders CC. Cefepime: the next generation? Clin Infect Dis 1993 Sep; 17: 369\u201379","journal-title":"Clin Infect Dis"},{"issue":"11","key":"BF03256641_CR13","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1128\/AAC.35.11.2312","volume":"35","author":"MJ Pucci","year":"1991","unstructured":"Pucci MJ, Boice-Sowek J, Kessler RE, et al. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother 1991 Nov; 35(11): 2312\u20137","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.2","key":"BF03256641_CR14","first-page":"23","volume":"8","author":"R Fontana","year":"1996","unstructured":"Fontana R, Valisena S, Cornaglia G. Comparative affinities for penicillin-binding proteins of multipolar ionic amphoteric cephalosporins in Gram-negative bacteria. J Chemother 1996; 8Suppl. 2: 23\u201330","journal-title":"J Chemother"},{"key":"BF03256641_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00006454-200103000-00031","volume":"20","author":"RE Kessler","year":"2001","unstructured":"Kessler RE. Cefepime microbiologic profile and update. Pediatr Infect Dis J 2001; 20: 331\u20136","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"BF03256641_CR16","first-page":"17","volume":"12","author":"R Gomez-Lus","year":"2000","unstructured":"Gomez-Lus R, Navarro C, Egido P, et al. In vitro activity of cefepime and cefotaxime compared to six other agents against 350 penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Chemother 2000; 12(1): 17\u201321","journal-title":"J Chemother"},{"issue":"2","key":"BF03256641_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0732-8893(00)00234-0","volume":"39","author":"D Mathai","year":"2001","unstructured":"Mathai D, Lewis MT, Kugler KC, et al. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I-results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis 2001 Feb; 39(2): 105\u201316","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"BF03256641_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0732-8893(00)00115-2","volume":"37","author":"RN Jones","year":"2000","unstructured":"Jones RN, Croco MA, Kugler KC, et al. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 2000 Jun; 37(2):115\u201325","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl.T2","key":"BF03256641_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jac\/46.suppl_2.25","volume":"46","author":"MA Pfaller","year":"2000","unstructured":"Pfaller MA, Jones RN. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). J Antimicrob Chemother 2000 Sep; 46Suppl. T2: 25\u201337","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"BF03256641_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0732-8893(00)00125-5","volume":"37","author":"RN Jones","year":"2000","unstructured":"Jones RN, Jenkins SG, Hoban DJ, et al. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997\u20131998. Diagn Microbiol Infect Dis 2000 Jun; 37(2): 93\u20138","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"BF03256641_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0924-8579(00)00152-7","volume":"15","author":"RN Jones","year":"2000","unstructured":"Jones RN, Jenkins SG, Hoban DJ, et al. In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997\u20131998. Int J Antimicrob Agents 2000 Jul; 15(2): 111\u20138","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"BF03256641_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0732-8893(99)00118-2","volume":"36","author":"R Ramphal","year":"2000","unstructured":"Ramphal R, Hoban DJ, Pfaller MA, et al. Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997\u20131998. Diagn Microbiol Infect Dis 2000 Feb; 36(2): 125\u20139","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"BF03256641_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1086\/598640","volume":"29","author":"DJ Diekema","year":"1999","unstructured":"Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to Gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999 Sep; 29(3): 595\u2013607","journal-title":"Clin Infect Dis"},{"key":"BF03256641_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0732-8893(97)00158-2","volume":"30","author":"MA Pfaller","year":"1998","unstructured":"Pfaller MA, Jones RN, Doern GV, et al. Multicenter evaluation of the antimicrobial activity for six broad-spectrum \u03b2-lactams in Venezuela using the Etest method. Diagn Microbiol Infect Dis 1998 Jan; 30: 45\u201352","journal-title":"Diagn Microbiol Infect Dis"},{"key":"BF03256641_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0732-8893(97)00234-4","volume":"30","author":"RN Jones","year":"1998","unstructured":"Jones RN, Pfaller MA, Doern GV, et al. Antimicrobial activity and spectrum investigation of eight broad-spectrum \u03b2-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Infect Dis 1998 Mar; 30: 215\u201328","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"BF03256641_CR26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1128\/AAC.43.2.385","volume":"43","author":"GV Doern","year":"1999","unstructured":"Doern GV, Jones RN, Pfaller MA, et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 1999 Feb; 43(2): 385\u20139","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"BF03256641_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1086\/514953","volume":"27","author":"GV Doern","year":"1998","unstructured":"Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1998 Oct; 27(4): 764\u201370","journal-title":"Clin Infect Dis"},{"issue":"12","key":"BF03256641_CR28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s100960100628","volume":"20","author":"R Fontana","year":"2001","unstructured":"Fontana R, Lo Cascio G, Ligozzi M, et al. Antimicrobial susceptibility of respiratory isolates of Enterobacteriaceae and Staphylococcus aureus in Italy: incidence and trends over the period 1997\u20131999. Eur J Clin Microbiol Infect Dis 2001 Dec; 20(12): 854\u201363","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"BF03256641_CR29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1179\/acb.2001.044","volume":"56","author":"Y Glupczynski","year":"2001","unstructured":"Glupczynski Y, Garrino MG, Carpentier M, et al. Comparative in vitro activity of isepamicin and other antibiotics against Gram-negative bacilli from intensive care units (ICU) in Belgium. Acta Clin Belg 2001 Sep-2001 31; 56(5): 307\u201315","journal-title":"Acta Clin Belg"},{"key":"BF03256641_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1086\/313710","volume":"30","author":"AC Fluit","year":"2000","unstructured":"Fluit AC, Jones ME, Schmitz F-J, et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clin Infect Dis 2000 Mar; 30: 454\u201360","journal-title":"Clin Infect Dis"},{"issue":"2","key":"BF03256641_CR31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1179\/joc.2002.14.2.140","volume":"14","author":"H Leblebicioglu","year":"2002","unstructured":"Leblebicioglu H, Gunaydin M., Esen S, et al. Surveillance of antimicrobial resistance in Gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Chemother 2002; 14(2): 140\u20136","journal-title":"J Chemother"},{"key":"BF03256641_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0732-8893(99)00019-X","volume":"34","author":"K Yamaguchi","year":"1999","unstructured":"Yamaguchi K, Mathai D, Biedenbach DJ, et al. Evaluation of the in vitro activity of six broad-spectrum \u03b2-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Diagn Microbiol Infect Dis 1999 Jun; 34: 123\u201334","journal-title":"Diagn Microbiol Infect Dis"},{"key":"BF03256641_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0732-8893(99)00120-0","volume":"35","author":"MT Lewis","year":"1999","unstructured":"Lewis MT, Yamaguchi K, Biedenbach DJ, et al. In vitro evaluation of cefepime and other broad-spectrum \u03b2-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. Diagn Microbiol Infect Dis 1999 Dec; 35: 307\u201315","journal-title":"Diagn Microbiol Infect Dis"},{"key":"BF03256641_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0732-8893(02)00390-5","volume":"43","author":"RN Jones","year":"2002","unstructured":"Jones RN, Kirby JT, Beach ML, et al. Geographic variations in activity of broad-spectrum \u03b2-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997\u20132000). Diagn Microbiol Infect Dis 2002; 43: 239\u201343","journal-title":"Diagn Microbiol Infect Dis"},{"key":"BF03256641_CR35","volume-title":"Performance standards for antimicrobial susceptibility testing: eleventh informational supplement","author":"National Committee for Clinical Laboratory Standards","year":"2001","unstructured":"National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: eleventh informational supplement. Document M100-S11. Wayne, PA: NCCLS, 2001"},{"key":"BF03256641_CR36","volume-title":"Performance standards for antimicrobial susceptibility testing: twelfth informational supplement","author":"National Committee for Clinical Laboratory Standards","year":"2002","unstructured":"National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement. Document M100-S12. Wayne, PA: NCCLS, 2002"},{"issue":"11","key":"BF03256641_CR37","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1128\/JCM.40.11.4332-4333.2002","volume":"40","author":"RN Jones","year":"2002","unstructured":"Jones RN, Mutnick AH, Varnam DJ. Impact of modified nonmeningeal Streptococcus pneumoniae interpretitive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001). J Clin Microbiol 2002 Nov; 40(11): 4332\u20133","journal-title":"J Clin Microbiol"},{"issue":"3","key":"BF03256641_CR38","first-page":"149","volume":"13","author":"H Giamarellou","year":"1987","unstructured":"Giamarellou H, Sahin A, Chryssouli Z. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other \u03b2-lactams against multiresistant Gram-negative isolates. Drugs Exp Clin Res 1987; 13(3): 149\u201353","journal-title":"Drugs Exp Clin Res"},{"key":"BF03256641_CR39","unstructured":"Bowker KE, Wootton M, Holt HA, et al. Ro 63-9141 (Ro 63), a novel broad spectrum anti-MRSA pyrrolidinone cephalosporin: activity against clinically significant anaerobes [abstract no. F-23] plus poster presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA 1998 Sep, 238"},{"key":"BF03256641_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0732-8893(98)00111-4","volume":"32","author":"S-C Chang","year":"1998","unstructured":"Chang S-C, Fang C-T, Chen Y-C, et al. In vitro activity of meropenem against common pathogenic bacteria isolated in Taiwan. Diagn Microbiol Infect Dis 1998 Dec; 32: 273\u20139","journal-title":"Diagn Microbiol Infect Dis"},{"key":"BF03256641_CR41","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1128\/AAC.45.3.825-836.2001","volume":"45","author":"P Hebeisen","year":"2001","unstructured":"Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001 Mar; 45: 825\u201336","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0924-8579(98)00052-1","volume":"10","author":"JMT Hamilton-Miller","year":"1998","unstructured":"Hamilton-Miller JMT, Shah S. Comparative anti-anaerobic activity of Men 10700, a penem antibiotic. J Antimicrob Agents 1998; 10: 321\u20134","journal-title":"J Antimicrob Agents"},{"issue":"2","key":"BF03256641_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1128\/AAC.27.2.207","volume":"27","author":"RE Kessler","year":"1985","unstructured":"Kessler RE, Bies M, Buck RE, et al. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum \u03b2-lactam antibiotics. Antimicrob Agents Chemother 1985 Feb; 27(2): 207\u201316","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.5","key":"BF03256641_CR44","doi-asserted-by":"publisher","first-page":"S264","DOI":"10.1007\/BF01645538","volume":"19","author":"A Bauernfeind","year":"1991","unstructured":"Bauernfeind A, Schweighart S, Eberlein E, et al. In vitro activity and stability against novel \u03b2-lactamases of investigational \u03b2-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection 1991; 19Suppl. 5: S264\u201375","journal-title":"Infection"},{"issue":"2","key":"BF03256641_CR45","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1128\/AAC.35.2.259","volume":"35","author":"N-X Chin","year":"1991","unstructured":"Chin N-X, Gu J-W, Fang W, et al. In vitro activity and \u03b2-lactamase stability of GR69153, a new long-acting cephalosporin. Antimicrob Agents and Chemother 1991 Feb; 35(2): 259\u201366","journal-title":"Antimicrob Agents and Chemother"},{"key":"BF03256641_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/jac\/15.3.305","volume":"15","author":"AM Clarke","year":"1985","unstructured":"Clarke AM, Zemcov SJV, Wright JM. HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in vitro comparison with other \u03b2-lactam antibiotics. J Antimicrob Chemother 1985; 15: 305\u201310","journal-title":"J Antimicrob Chemother"},{"key":"BF03256641_CR47","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0732-8893(85)90039-2","volume":"3","author":"RN Jones","year":"1985","unstructured":"Jones RN, Barry AL, Packer RR. BMY28142, cefbuperazone (T-1982), and Sch34343 antimicrobial activity against 94 anaerobes compared to seven other antimicrobial agents. Diagn Microbiol Infect Dis 1985; 3: 263\u20138","journal-title":"Diagn Microbiol Infect Dis"},{"key":"BF03256641_CR48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jac\/17.4.441","volume":"17","author":"HC Neu","year":"1986","unstructured":"Neu HC, Chin N-X, Jules K, et al. The activity of BMY 28142 a new broad spectrum \u03b2-lactamase stable cephalosporin. J Antimicrob Chemother 1986; 17: 441\u201352","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"BF03256641_CR49","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1128\/AAC.32.11.1666","volume":"32","author":"HC Neu","year":"1988","unstructured":"Neu HC, Chin N-X, Novelli A. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1988 Nov; 32(11): 1666\u201375","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR50","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/BF01964272","volume":"9","author":"A King","year":"1990","unstructured":"King A, Boothman C, Phillips I. Comparative in vitro activity of cefpirome and cefepime, two new cephalsporins. Eur J Clin Microbiol Infect Dis 1990 Sep; 9: 677\u201385","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"BF03256641_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2165\/00003495-200262040-00001","volume":"62","author":"AM Sefton","year":"2002","unstructured":"Sefton AM. Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. Drugs 2002; 62(4): 557\u201366","journal-title":"Drugs"},{"issue":"Suppl.D","key":"BF03256641_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jac\/41.suppl_4.25","volume":"41","author":"DM Livermore","year":"1998","unstructured":"Livermore DM. \u03b2-Lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998; 41Suppl. D: 25\u201341","journal-title":"J Antimicrob Chemother"},{"key":"BF03256641_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0002-9343(97)00044-2","volume":"103","author":"JDD Pitout","year":"1997","unstructured":"Pitout JDD, Sanders CC, Sanders WE. Antimicrobial resistance with focus on \u03b2-lactam resistance in Gram-negative bacilli. Am J Med 1997; 103: 51\u20139","journal-title":"Am J Med"},{"key":"BF03256641_CR54","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/clinids\/24.3.487","volume":"24","author":"F Moosdeen","year":"1997","unstructured":"Moosdeen F. The evolution of resistance to cephalosporins. Clin Infect Dis 1997; 24: 487\u201393","journal-title":"Clin Infect Dis"},{"issue":"Suppl.2","key":"BF03256641_CR55","first-page":"57","volume":"8","author":"CC Sanders","year":"1996","unstructured":"Sanders CC. In vitro activity of fourth generation cephalosporins against Enterobacteriaceae producing extended-spectrum \u03b2-lactamases. J Chemother 1996; 8Suppl. 2: 57\u201362","journal-title":"J Chemother"},{"key":"BF03256641_CR56","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1099\/00221287-144-11-3003","volume":"144","author":"M Mallea","year":"1998","unstructured":"Mallea M, Chevalier J, Bornet C, et al. Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 1998 Nov; 144 (Pt 11): 3003\u20139","journal-title":"Microbiology"},{"issue":"Suppl.B","key":"BF03256641_CR57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/jac\/32.suppl_B.87","volume":"32","author":"GG Grassi","year":"1993","unstructured":"Grassi GG, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother 1993; 32Suppl. B: 87\u201394","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"BF03256641_CR58","first-page":"196","volume":"1","author":"AC Gales","year":"1997","unstructured":"Gales AC, Bolmstr\u00f6m A, Sampaio J, et al. Antimicrobial susceptibiluty of Klebsiella pneumoniae producing extended-spectrum \u03b2-lactamase (ESBL) isolated in hospitals in Brazil. Braz J Infect Dis 1997; 1(4): 196\u2013203","journal-title":"Braz J Infect Dis"},{"issue":"6","key":"BF03256641_CR59","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1128\/JCM.40.6.2153-2162.2002","volume":"40","author":"FJ P\u00e9rez-P\u00e9rez","year":"2002","unstructured":"P\u00e9rez-P\u00e9rez FJ, Hanson ND. Detection of plasmid-mediated AmpC \u03b2-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002 Jun; 40(6): 2153\u201362","journal-title":"J Clin Microbiol"},{"key":"BF03256641_CR60","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1128\/AAC.43.8.1924","volume":"43","author":"A Bauernfeind","year":"1999","unstructured":"Bauernfeind A, Schneider I, Jungwirth R, et al. A novel type of AmpC \u03b2-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrob Agents Chemother 1999 Aug; 43: 1924\u201331","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR61","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1086\/340742","volume":"35","author":"R Odeh","year":"2002","unstructured":"Odeh R, Hujer AM, Bonomo RA, et al. Broad resistance due to plasmid-mediated AmpC \u03b2-lactamases in clinical isolates of Escherichia coli. Clin Infect Dis 2002; 35: 140\u20135","journal-title":"Clin Infect Dis"},{"issue":"3","key":"BF03256641_CR62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0732-8893(98)00039-X","volume":"31","author":"RN Jones","year":"1998","unstructured":"Jones RN, Wilson WR. Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections. Diagn Microbiol Infect Dis 1998 Jul; 31(3): 453\u20139","journal-title":"Diagn Microbiol Infect Dis"},{"key":"BF03256641_CR63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/jac\/43.1.55","volume":"43","author":"WC Chan","year":"1999","unstructured":"Chan WC, Li RC, Ling JM, et al. Markedly different rates and resistance profiles exhibited by seven commonly used and newer \u03b2-lactams on the selection of resistant variants of Enterobacter cloacae. J Antimicrob Chemother 1999 Jan; 43: 55\u201360","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"BF03256641_CR64","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1046\/j.1469-0691.2001.00225.x","volume":"7","author":"H Carsenti-Etesse","year":"2001","unstructured":"Carsenti-Etesse H, Cavallo JD, Roger PM, et al. Effect of \u03b2-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 2001 Mar; 7(3): 144\u201351","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"BF03256641_CR65","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1053\/srin.2002.34689","volume":"17","author":"BA Cunha","year":"2002","unstructured":"Cunha BA. Pseudomonas aeruginosa: resistance and therapy. Semin Respir Infect 2002 Sep; 17(3): 231\u20139","journal-title":"Semin Respir Infect"},{"issue":"Suppl.2","key":"BF03256641_CR66","first-page":"52","volume":"39","author":"N Kato","year":"1991","unstructured":"Kato N, Bando K, Muto Y, et al. Effect of parenteral cefepime on human fecal flora. Chemotherapy Tokyo 1991 Jun; 39Suppl. 2: 52\u20138","journal-title":"Chemotherapy Tokyo"},{"key":"BF03256641_CR67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jac\/30.3.365","volume":"30","author":"K B\u00e4cher","year":"1992","unstructured":"B\u00e4cher K, Schaeffer M, Lode H, et al. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother 1992 Sep; 30: 365\u201375","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"BF03256641_CR68","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/jac\/49.3.445","volume":"49","author":"PG Ambrose","year":"2002","unstructured":"Ambrose PG, Owens Jr RC, Garvey MJ, et al. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002 Mar; 49(3): 445\u201353","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"BF03256641_CR69","doi-asserted-by":"publisher","first-page":"19S","DOI":"10.1378\/chest.115.suppl_1.19S","volume":"115","author":"DS Burgess","year":"1999","unstructured":"Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999 Mar; 115(3): 19S\u201323S","journal-title":"Chest"},{"issue":"11","key":"BF03256641_CR70","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1046\/j.1198-743x.2001.00295.x","volume":"7","author":"MR Jacobs","year":"2001","unstructured":"Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetics and pharmacodynamic parameters. Clin Microbiol Infect 2001 Nov; 7(11): 589\u201396","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"BF03256641_CR71","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1592\/phco.19.18.1392.30900","volume":"19","author":"MB Kays","year":"1999","unstructured":"Kays MB. Comparison of five \u03b2-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances. Pharmacotherapy 1999 Dec; 19(12): 1392\u20139","journal-title":"Pharmacotherapy"},{"issue":"Suppl.74","key":"BF03256641_CR72","first-page":"270","volume":"23","author":"J Kovarik","year":"1991","unstructured":"Kovarik J, Rozenberg-Arska M, Visser M, et al. Pharmacodynamics of cefepime. Scand J Infect Dis 1991; 23Suppl. 74: 270\u20133","journal-title":"Scand J Infect Dis"},{"key":"BF03256641_CR73","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0149-2918(00)87978-3","volume":"22","author":"DS Burgess","year":"2000","unstructured":"Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000 Jan; 22: 66\u201375","journal-title":"Clin Ther"},{"issue":"2","key":"BF03256641_CR74","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2165\/00003088-199325020-00002","volume":"25","author":"MP Okamoto","year":"1993","unstructured":"Okamoto MP, Nakahiro RK, Chin A, et al. Cefepime clinical pharmacokinetics. Clin Pharmacokinet 1993; 25(2): 88\u2013102","journal-title":"Clin Pharmacokinet"},{"key":"BF03256641_CR75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1358\/dot.1995.31.4.325308","volume":"31","author":"KC Chung","year":"1995","unstructured":"Chung KC, Gill MA. Cefepime: pharmacokinetics and metabolism. Drugs Today 1995 Jun; 31: 235\u20139","journal-title":"Drugs Today"},{"issue":"Suppl.6A","key":"BF03256641_CR76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0002-9343(96)00106-4","volume":"100","author":"M Rybak","year":"1996","unstructured":"Rybak M. The pharmacokinetic profile of a new generation of parenteral cephalosporin. Am J Med 1996 Jun 24; 100Suppl. 6A: 39\u201344","journal-title":"Am J Med"},{"issue":"Suppl.B","key":"BF03256641_CR77","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jac\/32.suppl_B.103","volume":"32","author":"P Van der Auwera","year":"1993","unstructured":"Van der Auwera P, Santella PJ. Pharmacokinetics of cefepime: a review. J Antimicrob Chemother 1993 Nov; 32Suppl. B: 103\u201315","journal-title":"J Antimicrob Chemother"},{"key":"BF03256641_CR78","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1128\/AAC.34.6.1118","volume":"34","author":"RH Barbhaiya","year":"1990","unstructured":"Barbhaiya RH, Forgue ST, Gleason CR, et al. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother 1990 Jun; 34: 1118\u201322","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR79","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1128\/AAC.36.3.552","volume":"36","author":"RH Barbhaiya","year":"1992","unstructured":"Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992 Mar; 36: 552\u20137","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR80","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/j.1552-4604.1990.tb03569.x","volume":"30","author":"RH Barbhaiya","year":"1990","unstructured":"Barbhaiya RH, Knupp CA, Tenney J, et al. Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects. J Clin Pharmacol 1990 Oct; 30: 900\u201310","journal-title":"J Clin Pharmacol"},{"key":"BF03256641_CR81","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1345\/aph.19067","volume":"33","author":"JC Garrelts","year":"1999","unstructured":"Garrelts JC, Wagner DJ. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion. Ann Pharmacother 1999 Dec; 33: 1258\u201361","journal-title":"Ann Pharmacother"},{"key":"BF03256641_CR82","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1128\/AAC.36.7.1382","volume":"36","author":"RH Barbhaiya","year":"1992","unstructured":"Barbhaiya RH, Knupp CA, Pfeffer M, et al. Lack of pharmacokinetic interaction between cefepime and amikacin in humans. Antimicrob Agents Chemother 1992 Jul; 36: 1382\u20136","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR83","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1128\/AAC.36.6.1181","volume":"36","author":"RH Barbhaiya","year":"1992","unstructured":"Barbhaiya RH, Knupp CA, Pittman KA. Effects of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother 1992 Jun; 36: 1181\u20135","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"BF03256641_CR84","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1128\/AAC.34.10.1885","volume":"34","author":"JM Kovarik","year":"1990","unstructured":"Kovarik JM, ter Maaten JC, Rademaker CM, et al. Pharmacokinetics of cefepime in patients with respiratory tract infections. Antimicrob Agents Chemother 1990 Oct; 34(10): 1885\u20138","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0090-9556(25)07107-7","volume":"19","author":"RH Barbhaiya","year":"1991","unstructured":"Barbhaiya RH, Knupp CA, Forgue ST, et al. Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab Dispos 1991 Jan-1991 28; 19: 68\u201373","journal-title":"Drug Metab Dispos"},{"key":"BF03256641_CR86","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/clpt.1990.149","volume":"48","author":"RH Barbhaiya","year":"1990","unstructured":"Barbhaiya RH, Knupp CA, Forgue ST, et al. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990 Sep; 48: 268\u201376","journal-title":"Clin Pharmacol Ther"},{"key":"BF03256641_CR87","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1128\/AAC.36.12.2676","volume":"36","author":"J Cronqvist","year":"1992","unstructured":"Cronqvist J, Nilsson-Ehle I, \u00d6qvist B, et al. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment. Antimicrob Agents Chemother 1992 Dec; 36: 2676\u201380","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR88","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1128\/AAC.45.11.3148-3155.2001","volume":"45","author":"RS Malone","year":"2001","unstructured":"Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001 Nov; 45: 3148\u201355","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR89","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s002280050721","volume":"56","author":"S Schmaldienst","year":"2000","unstructured":"Schmaldienst S, Traunm\u00fcller F, Burgmann H, et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol 2000 Apr; 56: 61\u20134","journal-title":"Eur J Clin Pharmacol"},{"key":"BF03256641_CR90","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1128\/AAC.36.7.1387","volume":"36","author":"RH Barbhaiya","year":"1992","unstructured":"Barbhaiya RH, Knupp CA, Pfeffer M, et al. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1992 Jul; 36: 1387\u201391","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR91","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1128\/AAC.41.8.1783","volume":"41","author":"MD Reed","year":"1997","unstructured":"Reed MD, Yamashita TS, Knupp CK, et al. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. Antimicrob Agents Chemother 1997 Aug; 41: 1783\u20137","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR92","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00006454-200103000-00032","volume":"20","author":"JL Blumer","year":"2001","unstructured":"Blumer JL, Reed MD, Knupp C. Review of the pharmacokinetics of cefepime in children. Pediatr Infect Dis J 2001; 20: 337\u201342","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"BF03256641_CR93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1128\/AAC.31.1.55","volume":"31","author":"RH Barbhaiya","year":"1987","unstructured":"Barbhaiya RH, Forgue ST, Shyu WC, et al. High-pressure liquid chromatogrpahic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother 1987 Jan; 31(1): 55\u20139","journal-title":"Antimicrob Agents Chemother"},{"key":"BF03256641_CR94","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/jac\/25.6.959","volume":"25","author":"D Chadha","year":"1990","unstructured":"Chadha D, Wise R, Baldwin DR, et al. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose. J Antimicrob Chemother 1990 Jun; 25: 959\u201363","journal-title":"J Antimicrob Chemother"},{"key":"BF03256641_CR95","unstructured":"Breilh D, Delaisement C, Fratta A, et al. Estimation of cefepime lung diffusion using NONMEM population pharmacokinetic approach [abstract no. A-52]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada 1997 Sep, 11"},{"key":"BF03256641_CR96","first-page":"13","volume":"27","author":"E Boselli","year":"2002","unstructured":"Boselli E, Allaouchiche B, Breilh D, et al. Diffusion into lung tissue of cefepime administered in continuous infusion in patients with nosocomial pneumonia [abstract no. A-1260]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA 2002; 27: 13","journal-title":"42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA"},{"issue":"Suppl.2","key":"BF03256641_CR97","first-page":"175","volume":"39","author":"Y Goto","year":"1991","unstructured":"Goto Y, Yamazaki T, Nagai H, et al. Antimicrobial activity and sputum levels of a new cephem antibiotic cefepime [in Japanese]. Chemotherapy Tokyo 1991 Jun; 39Suppl. 2: 175\u20139","journal-title":"Chemotherapy Tokyo"},{"issue":"4","key":"BF03256641_CR98","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1179\/joc.1999.11.4.273","volume":"11","author":"P Bonfitto","year":"1999","unstructured":"Bonfitto P, Lamorgese V, De Vietro T, et al. A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia. J Chemother 1999 Aug; 11(4): 273\u20137","journal-title":"J Chemother"},{"issue":"4","key":"BF03256641_CR99","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/jac\/28.4.569","volume":"28","author":"H Edelstein","year":"1991","unstructured":"Edelstein H, Chirurgi V, Oster S, et al. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. J Antimicrob Chemother 1991 Oct; 28(4): 569\u201375","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl.B","key":"BF03256641_CR100","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jac\/32.suppl_B.165","volume":"32","author":"P L\u00e9ophonte","year":"1993","unstructured":"L\u00e9ophonte P, Bertrand A, Nouvet G, et al. A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother 1993 Nov; 32Suppl. B: 165\u201373","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"BF03256641_CR101","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/jac\/43.4.549","volume":"43","author":"RF Grossman","year":"1999","unstructured":"Grossman RF, Campbell DA, Landis SJ, et al. Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother 1999 Apr; 43(4): 549\u201354","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"BF03256641_CR102","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.42.4.729","volume":"42","author":"M Zervos","year":"1998","unstructured":"Zervos M, Nelson M. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 1998 Apr; 42(4): 729\u201333","journal-title":"Antimicrob Agents Chemother"},{"issue":"6A","key":"BF03256641_CR103","doi-asserted-by":"publisher","first-page":"52S","DOI":"10.1016\/S0002-9343(96)00108-8","volume":"100","author":"WJ Holloway","year":"1996","unstructured":"Holloway WJ, Palmer D. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections. Am J Med 1996 Jun 24; 100(6A): 52S\u20139S","journal-title":"Am J Med"},{"issue":"2","key":"BF03256641_CR104","first-page":"131","volume":"34","author":"J-C Lin","year":"2001","unstructured":"Lin J-C, Yeh K-M, Peng M-Y, et al. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia. J Microbiol Immunol Infect 2001 Jun; 34(2): 131\u20137","journal-title":"J Microbiol Immunol Infect"},{"issue":"6A","key":"BF03256641_CR105","doi-asserted-by":"publisher","first-page":"60S","DOI":"10.1016\/S0002-9343(96)00109-X","volume":"100","author":"R McCabe","year":"1996","unstructured":"McCabe R, Chirurgi V, Farkas SA, et al. A new therapeutic option for the treatment of pneumonia. Am J Med 1996 Jun 24; 100(6A): 60S\u20137S","journal-title":"Am J Med"},{"issue":"7","key":"BF03256641_CR106","doi-asserted-by":"crossref","first-page":"859","DOI":"10.11150\/kansenshogakuzasshi1970.66.859","volume":"66","author":"A Saito","year":"1992","unstructured":"Saito A, Shigeno Y, Irabu Y, et al. A comparative study of cefepime for bacterial pneumonia [in Japanese]. Kansenshogaku Zasshi 1992 Jul; 66(7): 859\u201385","journal-title":"Kansenshogaku Zasshi"},{"issue":"4","key":"BF03256641_CR107","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jac\/48.4.527","volume":"48","author":"E Cordero","year":"2001","unstructured":"Cordero E, Bouza E, Ruiz I, et al. Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial. J Antimicrob Chemother 2001 Oct; 48(4): 527\u201334","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"BF03256641_CR108","first-page":"636","volume":"15","author":"R Willis","year":"1998","unstructured":"Willis R, Gaines J, Nelson M. Cefepime vs cefotaxime in the treatment of pneumonia. Infections in Medicine 1998; 15(9): 636\u20138+640\u2013643","journal-title":"Infections in Medicine"},{"issue":"5","key":"BF03256641_CR109","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/00019048-199906000-00005","volume":"8","author":"PG Ambrose","year":"1999","unstructured":"Ambrose PG, Richerson MA, Stanton M-E, et al. Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia. Infect Dis Clin Pract 1999; 8(5): 245\u201351","journal-title":"Infect Dis Clin Pract"},{"issue":"Suppl.1","key":"BF03256641_CR110","first-page":"135","volume":"6","author":"G Zanetti","year":"2000","unstructured":"Zanetti G, Bally F, Aymon D, et al. Cefepime vs imipenem for nosocomial pneumonia in ICU patients. Clin Microbiol Infect 2000; 6Suppl. 1: 135","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"BF03256641_CR111","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00006454-200103000-00033","volume":"20","author":"JS Bradley","year":"2001","unstructured":"Bradley JS, Arrieta A. Empiric use of cefepime in the treatment of lower respiratory tract infections in children. Pediatr Infect Dis J 2001 Mar; 20(3): 343\u20139","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"BF03256641_CR112","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0750-7658(99)90093-X","volume":"18","author":"G Beaucaire","year":"1999","unstructured":"Beaucaire G, Nicolas MH, Martin C, et al. Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study [in French]. Ann Fr Anesth Reanim 1999 Feb; 18(2): 186\u201395","journal-title":"Ann Fr Anesth Reanim"},{"issue":"3","key":"BF03256641_CR113","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0732-8893(89)90023-0","volume":"12","author":"N Clynes","year":"1989","unstructured":"Clynes N, Scully BE, Neu HC. The use of cefepime (BMY 28142) to treat respiratory infections. Diagn Microbiol Infect Dis 1989; 12(3): 257\u201360","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"BF03256641_CR114","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1590\/S0104-42301999000100002","volume":"45","author":"EA de Medeiros","year":"1999","unstructured":"de Medeiros EA. Treatment of pneumonia in hospitalized patients: results of a multicenter study using a fourth-generation cephalosporin (cefepime) [in Portugese]. Rev Assoc Med Bras 1999 Jan-1999 31; 45(1): 2\u20138","journal-title":"Rev Assoc Med Bras"},{"issue":"Suppl.B","key":"BF03256641_CR115","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jac\/32.suppl_B.123","volume":"32","author":"H Giamarellou","year":"1993","unstructured":"Giamarellou H. Low-dosage cefepime as treatment for serious bacterial infections. J Antimicrob Chemother 1993 Nov; 32Suppl. B: 123\u201332","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl.B","key":"BF03256641_CR116","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/jac\/32.suppl_B.133","volume":"32","author":"Y Mouton","year":"1993","unstructured":"Mouton Y, Chidiac C, Humbert G, et al. A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections. J Antimicrob Chemother 1993 Nov; 32Suppl. B: 133\u201340","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"BF03256641_CR117","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1128\/AAC.34.6.954","volume":"34","author":"S Oster","year":"1990","unstructured":"Oster S, Edelstein H, Cassano K, et al. Open trial of cefepime (BMY 28142) for infections in hospitalized patients. Antimicrob Agents Chemother 1990 Jun; 34(6): 954\u20137","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"BF03256641_CR118","first-page":"29","volume":"50","author":"A Saito","year":"2002","unstructured":"Saito A, Otsuka M, Kobayashi K, et al. Clinical efficacy of cefepime in nonresponders to other antibiotics of postmarketing special surveillance. Jpn J Chemother 2002; 50(1): 29\u201346","journal-title":"Jpn J Chemother"},{"issue":"6A","key":"BF03256641_CR119","doi-asserted-by":"publisher","first-page":"68S","DOI":"10.1016\/S0002-9343(96)00110-6","volume":"100","author":"HC Neu","year":"1996","unstructured":"Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med 1996; 100(6A): 68S\u201375S","journal-title":"Am J Med"},{"issue":"4","key":"BF03256641_CR120","first-page":"124","volume":"15","author":"HLL Gubbelmans","year":"1990","unstructured":"Gubbelmans HLL, Materman ES, Maesen FPV. Cefepime versus ceftriaxone: a tolerance study by intramuscular injection. Tijdschr Ther Geneesm Onderz 1990; 15(4): 124\u20136","journal-title":"Tijdschr Ther Geneesm Onderz"},{"issue":"11","key":"BF03256641_CR121","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1212\/WNL.55.11.1756","volume":"55","author":"JT Fishbain","year":"2000","unstructured":"Fishbain JT, Monahan TP, Canonico MM. Cerebral manifestations of cefepime toxicity in a dialysis patient. Neurology 2000 Dec; 55(11): 1756\u20137","journal-title":"Neurology"},{"key":"BF03256641_CR122","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1212\/WNL.54.11.2153","volume":"54","author":"S Dixit","year":"2000","unstructured":"Dixit S, Kurle P, Buyan-Dent L, et al. Status epilepticus associated with cefepime. Neurology 2000 Jun; 54: 2153\u20135","journal-title":"Neurology"},{"issue":"Suppl.1","key":"BF03256641_CR123","first-page":"315","volume":"8","author":"M Michels","year":"2002","unstructured":"Michels M, De Keulenaer B, Zachee P, et al. Cefepime and nonconvulsive status epilepticus (NCSE) in renal failure (RF) patients [abstract no. P1351]. Clin Microbiol Infect 2002 Apr; 8Suppl. 1:315","journal-title":"Clin Microbiol Infect"},{"key":"BF03256641_CR124","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00134-001-1170-9","volume":"28","author":"D Chatellier","year":"2002","unstructured":"Chatellier D, Jourdain M, Mangalaboyi J, et al. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002 Feb; 28: 214\u20137","journal-title":"Intensive Care Med"},{"issue":"6","key":"BF03256641_CR125","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2165\/00019053-199405060-00006","volume":"5","author":"JA Paladino","year":"1994","unstructured":"Paladino JA. Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis. Pharmacoeconomics 1994; 5(6): 505\u201312","journal-title":"Pharmacoeconomics"},{"key":"BF03256641_CR126","unstructured":"American Lung Association. Fact sheet: pneumonia [web page]. 2002 Oct. Available from: URL: http:\/\/www.lungusa.org\/diseases\/pneumonia_factsheet.html. (accessed 2003 Jan 17)"},{"key":"BF03256641_CR127","unstructured":"European Respiratory Society. Preliminary data from the European White Book on Lung Disease [web page]. 2002 Sep. Available from: URL:http:\/\/www.ersnet.org\/4\/3\/4_4_2_6.asp. (accessed 2003 Jan 17)"},{"issue":"7","key":"BF03256641_CR128","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","volume":"163","author":"American Thoracic Society","year":"2001","unstructured":"American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001 Jun; 163(7): 1730\u201354","journal-title":"Am J Respir Crit Care Med"},{"key":"BF03256641_CR129","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.153.5.8630626","volume":"153","author":"American Thoracic Society","year":"1996","unstructured":"American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: a consensus statement. Am J Respir Crit Care Med 1996; 153: 1711\u201325","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"BF03256641_CR130","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/archinte.162.16.1849","volume":"162","author":"F Arancibia","year":"2002","unstructured":"Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa. Incidence, risk, and prognosis. Arch Intern Med 2002; 162(16): 1849\u201358","journal-title":"Arch Intern Med"},{"issue":"2","key":"BF03256641_CR131","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1086\/313954","volume":"31","author":"JG Bartlett","year":"2000","unstructured":"Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000 Aug; 31(2): 347\u201382","journal-title":"Clin Infect Dis"},{"issue":"1","key":"BF03256641_CR132","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2165\/00003495-199855010-00003","volume":"55","author":"RG Finch","year":"1998","unstructured":"Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998 Jan; 55(1): 31\u201345","journal-title":"Drugs"},{"issue":"2","key":"BF03256641_CR133","doi-asserted-by":"publisher","first-page":"373S","DOI":"10.1378\/chest.119.2_suppl.373S","volume":"119","author":"JP Lynch III","year":"2001","unstructured":"Lynch III JP. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119(2): 373S\u201384S","journal-title":"Chest"},{"issue":"6","key":"BF03256641_CR134","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0025-7125(05)70397-7","volume":"85","author":"JJT Cross","year":"2001","unstructured":"Cross JJT, Campbell GD. Therapy of nosocomial pneumonia. Med Clin North Am 2001 Nov; 85(6): 1583\u201394","journal-title":"Med Clin North Am"},{"issue":"10","key":"BF03256641_CR135","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","volume":"160","author":"JD Heffelfinger","year":"2000","unstructured":"Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000 May 22; 160(10): 1399\u2013408","journal-title":"Arch Intern Med"},{"issue":"2","key":"BF03256641_CR136","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1086\/313959","volume":"31","author":"LA Mandell","year":"2000","unstructured":"Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000 Aug; 31(2): 383\u2013421","journal-title":"Clin Infect Dis"},{"issue":"3","key":"BF03256641_CR137","doi-asserted-by":"crossref","first-page":"180","DOI":"10.7861\/clinmedicine.1-3-180","volume":"1","author":"WS Lim","year":"2001","unstructured":"Lim WS, Macfarlane JT. Hospital-acquired pneumonia. Clin Med 2001 May-2001 30; 1(3): 180\u20134","journal-title":"Clin Med"},{"issue":"1","key":"BF03256641_CR138","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003495-199651010-00008","volume":"51","author":"JA Balfour","year":"1996","unstructured":"Balfour JA, Bryson HM, Brogden RN. Imipenem\/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996 Jan; 51(1): 99\u2013136","journal-title":"Drugs"},{"issue":"1","key":"BF03256641_CR139","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00003495-199550010-00007","volume":"50","author":"LR Wiseman","year":"1995","unstructured":"Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50(1): 73\u2013101","journal-title":"Drugs"},{"issue":"1","key":"BF03256641_CR140","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-200262010-00002","volume":"62","author":"GG Zhanel","year":"2002","unstructured":"Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs 2002; 62(1): 13\u201359","journal-title":"Drugs"},{"issue":"1","key":"BF03256641_CR141","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00003495-200059010-00010","volume":"59","author":"JA Barman Balfour","year":"2000","unstructured":"Barman Balfour JA, Lamb HA. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000 Jan; 59(1): 115\u201339","journal-title":"Drugs"},{"issue":"3","key":"BF03256641_CR142","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00002018-200124030-00004","volume":"24","author":"SJ Martin","year":"2001","unstructured":"Martin SJ, Jung R, Garvin CG. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Drug Saf 2001; 24(3): 199\u2013222","journal-title":"Drug Saf"},{"issue":"1","key":"BF03256641_CR143","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00003495-200262010-00007","volume":"62","author":"CM Perry","year":"2002","unstructured":"Perry CM, Omrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002; 62(1): 169\u2013207","journal-title":"Drugs"}],"container-title":["American Journal of Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF03256641\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T03:39:51Z","timestamp":1743997191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF03256641"}},"subtitle":["A Review of its Use in the Management of Hospitalized Patients with Pneumonia"],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["BF03256641"],"URL":"https:\/\/doi.org\/10.1007\/bf03256641","relation":{},"ISSN":["1175-6365"],"issn-type":[{"value":"1175-6365","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]},"assertion":[{"value":"20 August 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}